<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208490</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00060694</org_study_id>
    <secondary_id>NCI-2019-03600</secondary_id>
    <nct_id>NCT04208490</nct_id>
  </id_info>
  <brief_title>Implementation and Effectiveness Trial of HN-STAR</brief_title>
  <acronym>HN-STAR</acronym>
  <official_title>Implementation and Effectiveness Trial of HN-STAR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      People who have been treated for head and neck cancer (HNC survivors) can experience serious&#xD;
      consequences from their cancer and its treatment, ongoing risks of new cancers, and other&#xD;
      unrelated illnesses. These concerns pose challenges to the provision of comprehensive care to&#xD;
      HNC survivors. We created HN-STAR to facilitate and tailor the ongoing care of HNC survivors.&#xD;
      Survivors use HN-STAR on a computer or tablet to answer questions about symptoms and health&#xD;
      concerns before a routine visit with a cancer care provider. During the clinic visit, the&#xD;
      provider uses HN-STAR to see evidence-based recommendations for managing each concern&#xD;
      reported by the survivor. The provider and survivor discuss recommendations and select&#xD;
      appropriate actions (e.g., testing, referrals, prescriptions, self-management). HN-STAR&#xD;
      produces a survivorship care plan that includes all reported concerns and the actions&#xD;
      selected in clinic. The survivorship care plan is given to the survivor and the primary care&#xD;
      provider. Three months, six months, and nine months later, the survivor uses HN-STAR from&#xD;
      home (or clinic) to report their concerns again, and a new survivorship care plan is created&#xD;
      each time.&#xD;
&#xD;
      Our trial randomizes ≥30 oncology practices from the National Community Oncology Research&#xD;
      Program to use HN-STAR or provide usual care to 350 recent survivors of head and neck cancer.&#xD;
      We hypothesize that survivors in the HN-STAR arm will have greater improvement in&#xD;
      patient-centered outcomes (including cancer-related well-being, symptoms, and patient&#xD;
      activation) over one year compared to survivors in the usual care arm, measured by surveys at&#xD;
      baseline and one year later. We also hypothesize that survivors in the HN-STAR arm will be&#xD;
      more likely to receive care that is aligned with evidence-based recommendations during the&#xD;
      year of the study than survivors in the usual care arm. Our final aim investigates the&#xD;
      implementation of HN-STAR in clinical practice, using interviews and surveys of survivors,&#xD;
      providers, and other clinic staff to understand the feasibility, acceptability,&#xD;
      appropriateness, and other aspects of providing survivorship care to head and neck cancer&#xD;
      survivors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HNC-Specific QOL</measure>
    <time_frame>Baseline &amp; 1 year</time_frame>
    <description>Measured using Trial Outcome Index from the Functional Assessment of Cancer Therapy Head and Neck. It is a 23-item summary measure that ranges from 0 to a maximum of 96 where higher scores indicate better overall physical and functional outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in QoL</measure>
    <time_frame>Baseline &amp; 1 year</time_frame>
    <description>Measured using domains and overall measures from the FACT H&amp;N. The total score evaluates overall QoL in Head and Neck Cancer patients and ranges from 0 to 144, with higher scores indicating better overall QoL. Subscales are calculated by summing the relevant questions [answered using a Likert scale ranging from 0 (Not at all) to 4 (Very much)]. Higher scores on subscales represent a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QoL</measure>
    <time_frame>Baseline &amp; 1 year</time_frame>
    <description>Measured using scales from the EORTC QLQ-C30. Scales from the EORTC QLQ-C30 evaluate functional status, global health status and symptoms. All scales range from 0 to 100, with higher scores representing higher functioning, QoL or symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change symptom burden</measure>
    <time_frame>Baseline &amp; 1 year</time_frame>
    <description>Measured using scales from the EORTC QLQ-HN43. Symptom subscales from the EORTC QLQ- HN43 range from 0 to 100, with higher scores representing higher symptom burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptom burden</measure>
    <time_frame>Baseline &amp; 1 year</time_frame>
    <description>Measured using PRO-CTCAE items for relevant symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain</measure>
    <time_frame>Baseline &amp; 1 year</time_frame>
    <description>Measured using Brief Pain Inventory Short Form. Pain severity and interference items are measured using a scale from 0 to 10, with higher scores indicating worse pain or interference. The average is used as a summary measure of pain severity and pain interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient activation</measure>
    <time_frame>Baseline &amp; 1 year</time_frame>
    <description>Measured using Patient Activation Measure Short Form. PAM score ranges from 0 to 100, with higher score meaning higher level of activation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perceived quality of cancer care</measure>
    <time_frame>Baseline &amp; 1 year</time_frame>
    <description>Measured using the CAHPS® Cancer Care Survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence and surveillance of guideline concordant care</measure>
    <time_frame>These variables will be derived from the medical record during the year following the initial visit.</time_frame>
    <description>Rate at which survivors had ≥1 visit to a primary care provider in the year following the initial visit will be compared by arm. Receipt or non-receipt of guideline-concordant cancer surveillance will be derived from the oncology medical records and compared by arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">470</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>HN-STAR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HN-STAR Intervention</intervention_name>
    <description>The Head and Neck Survivorship Tool (HN-STAR) is a web-based tool used to assist clinicians in implementing the ACS/ASCO HNC survivorship guidelines.</description>
    <arm_group_label>HN-STAR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Survivor Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years.&#xD;
&#xD;
          -  Diagnosis of head and neck squamous cell carcinoma, specifically oral cavity, larynx,&#xD;
             any part of pharynx and unknown squamous cell carcinoma primary.&#xD;
&#xD;
          -  Completed chemotherapy and/or radiation therapy for head and neck squamous cell&#xD;
             carcinoma ≤ 6 months prior to enrollment.&#xD;
&#xD;
          -  Deemed free of disease at last assessment.&#xD;
&#xD;
          -  Cognitively and physically able to complete study survey per local NCORP site staff&#xD;
             discretion.&#xD;
&#xD;
          -  Scheduled for a clinic visit with a provider who has agreed to participate in this&#xD;
             study and meets requirements for the arm to which their practice has been assigned&#xD;
             (the practice designated clinician) for routine follow-up.&#xD;
&#xD;
          -  Willing to complete study assessments 3, 6, and 9 months after the designated clinic&#xD;
             visit either 1) remotely (via smartphone, tablet, or computer) or 2) at the clinic to&#xD;
             complete study assessments on a clinic tablet or computer.&#xD;
&#xD;
        Survivor Exclusion Criteria:&#xD;
&#xD;
          -  History of any other cancer, other than non-melanoma skin disease.&#xD;
&#xD;
          -  Head and neck tumor histology of lymphoma, adenocarcinoma or melanoma.&#xD;
&#xD;
          -  Diagnosed with a prior primary head and neck cancer.&#xD;
&#xD;
          -  Does not speak or read English, because the HN-STAR tool is only available in English&#xD;
             at this time.&#xD;
&#xD;
          -  Received only surgery as treatment for head and neck cancer.&#xD;
&#xD;
          -  Current, planned enrollment, or in follow-up on another interventional symptom&#xD;
             management study protocol, as per patient self-report or research staff members'&#xD;
             knowledge at the time of consent. Concurrent participation in treatment or imaging&#xD;
             studies is allowed.&#xD;
&#xD;
        Designated Clinician Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; = 18 years&#xD;
&#xD;
          -  MD, DO, NP, or PA&#xD;
&#xD;
          -  Able to speak and read English, because the HN-STAR tool is only available in English&#xD;
             at this time.&#xD;
&#xD;
          -  Routinely provides care for cancer patients or survivors.&#xD;
&#xD;
          -  Willing to complete study-specific trainings and incorporate HN-STAR or provide usual&#xD;
             care in a routine follow-up care visit&#xD;
&#xD;
        Stakeholders Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; = 18&#xD;
&#xD;
          -  Member of the practice clinical or administrative team who is involved in the&#xD;
             oversight of the delivery of head and neck cancer survivorship care or who would make&#xD;
             decisions about implementing head and neck survivorship tools such as HN-STAR. This&#xD;
             could include clinic administrators, nurse navigators, key clinical team members,&#xD;
             program directors, information technology specialists, and other staff (e.g., service&#xD;
             line or nursing leaders).&#xD;
&#xD;
          -  Employed for at least one month at the practice.&#xD;
&#xD;
          -  Able to speak and reads English, because the HN-STAR tool is only available in English&#xD;
             at this time.&#xD;
&#xD;
        Stakeholder Exclusion Criteria:&#xD;
&#xD;
          -  Is the designated clinician at the practice.&#xD;
&#xD;
        Primary Care Provider Inclusion Criteria:&#xD;
&#xD;
          -  Provides primary care (general preventative care) to a survivor enrolled in the&#xD;
             HN-STAR study.&#xD;
&#xD;
          -  Age &gt;= 18&#xD;
&#xD;
          -  MD, DO, NP, or PA&#xD;
&#xD;
        Primary Care Provider Exclusion Criteria:&#xD;
&#xD;
          -  Provides Oncology Care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen Craver</last_name>
    <phone>336-716-0891</phone>
    <email>NCORP@wakehealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carle on Vermilion</name>
      <address>
        <city>Danville</city>
        <state>Illinois</state>
        <zip>61832</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Tanmay Sahai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>217-876-4740</phone>
      <email>rhamrick@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Physician Group-Mattoon/Charleston</name>
      <address>
        <city>Mattoon</city>
        <state>Illinois</state>
        <zip>61938</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Tanmay Sahai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-446-5532</phone>
      <email>Research@carle.com</email>
    </contact>
    <investigator>
      <last_name>Tanmay Sahai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center - Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>308-398-6518</phone>
      <email>clinicaltrials@sfmc-gi.org</email>
    </contact>
    <investigator>
      <last_name>Richard L. Deming</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harold Alfond Center for Cancer Care</name>
      <address>
        <city>Augusta</city>
        <state>Maine</state>
        <zip>04330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>207-626-4855</phone>
    </contact>
    <investigator>
      <last_name>Vatche Tchekmedyian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Partners Otolaryngology</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>207-396-8670</phone>
      <email>ClinicalResearch@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Vatche Tchekmedyian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Partners - South Portland</name>
      <address>
        <city>South Portland</city>
        <state>Maine</state>
        <zip>04106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>207-396-8670</phone>
      <email>ClinicalResearch@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Vatche Tchekmedyian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Clinic - Saint Louis Park</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Pamala A. Pawloski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Pamala A. Pawloski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Roger Maris Cancer Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>701-234-6161</phone>
      <email>OncologyClinicalTrialsFargo@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AnMed Health Cancer Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-512-4651</phone>
      <email>rhonda.ballew@anmedhealth.org</email>
    </contact>
    <investigator>
      <last_name>Leander Cannick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>843-792-9321</phone>
      <email>hcc-clinical-trials@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Evan M. Graboyes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-603-6213</phone>
      <email>melissa_beckman@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Robert D. Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute - Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-522-2066</phone>
      <email>kim.williams3@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-603-6213</phone>
      <email>melissa_beckman@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Robert D. Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-560-6104</phone>
      <email>kmertz-rivera@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Amarinthia (Amy) Curtis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>605-312-3320</phone>
      <email>OncologyClinicalTrialsSF@SanfordHealth.org</email>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Saint Francis Medical Center</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>804-893-8663</phone>
      <email>Jaime_scott@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>William J. Irvin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ThedaCare Regional Cancer Center</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>920-364-3605</phone>
      <email>ResearchDept@thedacare.org</email>
    </contact>
    <investigator>
      <last_name>Harsha V. Poola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Survivorship</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.</ipd_description>
    <ipd_time_frame>6 months after publication for a 2 year duration</ipd_time_frame>
    <ipd_access_criteria>upon request to NCORP@wakehealth.edu</ipd_access_criteria>
    <ipd_url>https://nctn-data-archive.nci.nih.gov/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

